The Longest Day of the year, or summer solstice, happens on June 21, 2022. For this reason, the Alzheimer’s Association chose this day to raise awareness across the world about fighting the darkness of Alzheimer’s disease (AD) through fundraising. To shine a light on the physician burden of managing the AD journey for patients, SYNAPS Dx points …
SYNAPS Dx is pleased to join other leading health organizations and individuals to help raise awareness of the value of accurate, early diagnosis of Alzheimer’s Disease (AD) during June, Alzheimer’s & Brain Awareness Month. This important event shines a light on brain disorders, including AD as well as other dementias, as a major public health issue. Today, …
SYNAPS Dx (SDx) is pleased to present “Physicians’ Assessment of the Clinical Utility of a Novel Test to Diagnose Alzheimer’s Disease (AD),” at the Professional Society for Health Economics and Outcomes Research (ISPOR) Annual Conference, May 15-18, 2022, in National Harbor, Maryland. Our implicit preference study indicates that 90% of physicians would routinely use the results of DISCERN™, a diagnostic test …
First autopsy-validated, highly accurate, and minimally invasive DISCERN™ test is now available to support a clinician’s definitive diagnosis of Alzheimer’s Disease versus other, possibly curable conditions, giving individuals an opportunity to get the right treatment plan sooner—while giving families greater peace of mind. May is Older Americans Month (OAM) and a great time to focus on the needs of older …
SYNAPS Dx is pleased to announce our membership with the American Brain Coalition (ABC), a nonprofit organization comprising many of the United States’ leading patient advocacy and voluntary health organizations, as well as professional neurological, psychological and psychiatric associations. With our focus on early diagnosis of Alzheimer’s Disease (AD), our team looks forward to advancing research on …
A press release issued by Semler Scientific (SMLR) articulates its investment in SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of diagnostics for neurodegenerative disorders and conditions, including Alzheimer’s Disease (AD). The announcement points to SDx’s DISCERN™ and its role in the diagnosis of early-stage AD. “We believe this investment continues to distinguish the accuracy of …
Memory loss can be brought on by a number of treatable medical issues, including Lyme disease, vitamin deficiencies, thyroid issues, drug interactions and the various forms of dementia. Some of the conditions that are often mistaken for Alzheimer’s disease (AD) can easily be addressed with inexpensive interventions. Without a definitive diagnosis, however, it’s frustrating, expensive and overwhelming for patients and families, providers and payers to know how to proceed in the care journey. To demonstrate how a definite diagnosis is now possible, SYNAPS Dx has released a short video that illustrates in simple terms …
Biomarkers measure what is happening inside the living body, shown by the results of laboratory and imaging tests. They help clinicians and scientists diagnose diseases and health conditions, identify at-risk individuals, and monitor responses to treatment and changes over time. Many types of biomarker tests are used for research on Alzheimer’s disease (AD) and related dementias. This …
The emergence of new drugs and therapies for early stage Alzheimer’s disease (AD), known as mild cognitive impairment (MCI) or mild dementia, has intensified the challenge of identifying the most appropriate, cost-effective treatment for (AD). The risk-benefit of these new disease modifying agents has raised urgency for accurate tests to verify an AD diagnosis earlier in the disease …
An estimated 5.8 million Americans age 65 and older live with Alzheimer’s disease (AD), a progressive disease that destroys memory and other important mental functions, with projections showing that by 2050 that number will reach 12.7 million. AD tends to progress slowly in three general stages: early or mild cognitive impairment (MCI), moderate and severe. Because AD affects people in different ways, each person may experience …
Recent Comments